Torrent Pharmaceuticals Ltd shares hit a 52-week high of Rs 2,742.60 on March 6 after the company announced that it would receive EIR from the USFDA.
In its regulatory filing, the company said the US Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for the company's oral oncology manufacturing facilities in Bileshwarpura, Gujarat and He added that the inspection had been successfully closed by the US regulator.
The USFDA conducted a pre-approval inspection at the company's oral oncology manufacturing facility in Gujarat between December 5, 2023 and December 11, 2023.
Torrent Pharma is a flagship company of the Torrent Group and has been ranked among the top 10 in the Indian pharmaceutical market.
Earlier on February 2, the company had declared an interim dividend of Rs 22 per fully paid share of Rs 5, which will be paid on or around February 23.
At 3:30 pm, Torrent Pharma shares closed 1.24% higher at Rs 2,694.95 on NSE.
